Rockwell Medical Finalizes 1-for-10 Reverse Stock Split, Effective July 1
RMTI is trading near its 52-week low of $0.603 (0.2% below the low).
Summary
Rockwell Medical has filed the necessary amendment to implement a 1-for-10 reverse stock split, effective July 1, 2026, to address Nasdaq's minimum bid price requirement.
Key Events · Corporate Governance and Compliance · RMTI
-
Reverse Stock Split Implemented
The company filed a certificate of amendment to its certificate of incorporation to effect a 1-for-10 reverse stock split, effective 12:01 a.m. Eastern Time on July 1, 2026.
-
Nasdaq Compliance Measure
This action follows shareholder approval on June 12, 2026, and is a direct response to the Nasdaq non-compliance notice regarding the minimum $1.00 bid price requirement, aiming to maintain the company's listing.
-
Adjustments to Securities
Proportionate adjustments will be made to outstanding equity awards, the conversion price of Series X Convertible Preferred Stock, and the exercise price of warrants to reflect the new share count.
Analysis · RMTI · Life Sciences
This filing confirms the implementation of a 1-for-10 reverse stock split, a critical action for Rockwell Medical to regain compliance with Nasdaq's minimum bid price requirement. The company has been trading near its 52-week low, making this split essential to avoid potential delisting. This 8-K marks the final step in a process that included shareholder approval and prior Nasdaq non-compliance notices, providing clarity on the effective date and adjustments to other securities.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RMTI was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.7M. The 52-week trading range was $0.60 to $2.10. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.